Skip to main content

myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment

myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment

The myeloMATCH North American platform study is now open in Canada and comprises a series of clinical trials to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

“CCTG is thrilled to be a partner in the development and implementation of the myeloMATCH trials for AML and MDS. This collaboration affords Canadian cancer centers, investigators and, most importantly, our patients, the opportunity to participate in the most innovative approaches to diagnosis, treatment and follow-up,” says Dr Sarit Assouline, the CCTG hematologic disease site chair, Jewish General Hospital hematologist and associate professor at McGill University. "myeloMATCH is a dynamic platform that brings together experts from across North America and allows Canadians to be on the cutting edge of new developments in AML and MDS.” 

The group of myeloMATCH trials will test new precision medicine treatments for patients with myeloid cancers, from diagnosis through multiple stages of their treatment. In the screening study MDS and AML patients undergo biomarker testing to tell the study doctors which is the best myeloMATCH clinical trial based on the molecular drivers of their disease.TierPathway

If there is not a matching treatment trial, patients will go on to receive standard-of-care treatment with their physician and will continue to be followed on myeloMATCH via the Tier Advancement Pathway. 

“The Tier Advancement Pathway provides the opportunity for patients registered but who do not match a Tier study to continue within myeloMATCH and be constantly reassessed for possible assignment to subsequent Tier studies if available to them at the time while continuing to receive  the standard of care therapy at their institution,” says AL6 study co-chair, Dr Lynn Savoie Clinical Associate Professor, Division of Hematology and Hematologic Malignancies, University of Calgary.

Participants’ treatment and outcome data will be collected to further inform AML care in all patients. 

In Canada the first two trials are now available to those who meet the eligibility criteria: The AL6 (MM1YA-CTG01) study compares the usual treatment for acute myeloid leukemia (AML) with two different combinations of treatment; and the ALC8 (MM1YA-S01) study which will test new experimental treatment regimens that may work better at getting rid of more AML compared to the standard approach. 

Upcoming trials expected in 2025 are ALC9 which will test new experimental treatment regimens in high-risk disease and MD1 which explores combination therapy in lower risk MDS patients. 

Dr. Sarit Assouline Hematologic Committee Co-Chair
Dr Sarit Assouline 
CCTG Hematologic Committee Co-Chair 
AL6 study co-chair, Dr Lynn Savoie
Dr Lynn Savoie 
AL6 study co-chair  
Annette Hay Senior Investigator
Dr Annette Hay
CCTG Senior Investigator
Lois Shepherd Senior Investigator
Dr Lois Shepherd
CCTG Senior Investigator

 

 

 

 

 

 

 

 

 

DrAlyKarsan ALC7 study champion
Dr Aly Karsan ALC7 study champion
Dr Rena Buckstein MD1 study chair
Dr Rena Buckstein MD1 study chair
Dr Lee Mozessohn ALC6 study chair
Dr Lee Mozessohn ALC9 study champion
Dr. Guillaume Richard-Carpentier ALC8 Study Champion
Dr Guillaume Richard-Carpentier ALC8 Study Champion